Enumeral Biomedical Reports Year End 2016 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced its financial results for the year ended December 31, 2016.

“Over the last several months we have been actively engaged in our turnaround plans for Enumeral,” said Wael Fayad, the Company’s Chairman, Chief Executive Officer and President. “While our scientific team has been executing a plan to advance our programs and improve our capacity to innovate, we have also been positioning the Company for transformational opportunities. We continue to pursue arrangements to enhance our pipeline of next-generation therapeutics, including the potential acquisition or licensing of complementary assets that are at a more advanced stage of development than our own internally developed pipeline.”

“We recognize the challenges of our current financial position and the need to secure financing to enable us to advance our strategic plans,” continued Mr. Fayad. “To that end, we are exploring a range of potential transactions including financing arrangements, collaborations, mergers and acquisitions, as well as other strategic alternatives. If we are able to secure additional funding and execute on our plans, we believe that we can expand our pipeline and enhance our growth potential. We truly appreciate the continued support of our stockholders and other stakeholders, and we look forward to reporting on our progress.”

Back to news